Bull Flag Stocks
SNDX is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
SYNDAX PHARMACEUTICALS INC (SNDX) Stock Price & Overview
NASDAQ:SNDX • US87164F1057
Current stock price
24.25 USD
-0.19 (-0.78%)
At close:
24.01 USD
-0.24 (-0.99%)
After Hours:
The current stock price of SNDX is 24.25 USD. Today SNDX is down by -0.78%. In the past month the price increased by 3.19%. In the past year, price increased by 110.14%.
SNDX Key Statistics
52-Week Range8.58 - 25.59
Current SNDX stock price positioned within its 52-week range.
1-Month Range22.4 - 25.59
Current SNDX stock price positioned within its 1-month range.
- Market Cap
- 2.139B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.29
- Dividend Yield
- N/A
SNDX Stock Performance
Today
-0.78%
1 Week
-0.16%
1 Month
+3.19%
3 Months
+18.18%
Longer-term
6 Months +69.58%
1 Year +110.14%
2 Years +14.77%
3 Years +18.00%
5 Years +52.13%
10 Years +77.14%
SNDX Stock Chart
SNDX Stock Screens
SNDX currently appears in the following ChartMill screener lists.
SNDX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SNDX. When comparing the yearly performance of all stocks, SNDX is one of the better performing stocks in the market, outperforming 92.21% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SNDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNDX. Both the profitability and financial health of SNDX have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SNDX Earnings
On February 26, 2026 SNDX reported an EPS of -0.78 and a revenue of 68.73M. The company missed EPS expectations (-30.92% surprise) and beat revenue expectations (5.34% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.78
Revenue Reported68.728M
EPS Surprise -30.92%
Revenue Surprise 5.34%
SNDX Forecast & Estimates
20 analysts have analysed SNDX and the average price target is 41.06 USD. This implies a price increase of 69.3% is expected in the next year compared to the current price of 24.25.
For the next year, analysts expect an EPS growth of 42.81% and a revenue growth 109.31% for SNDX
Analysts
Analysts87
Price Target41.06 (69.32%)
EPS Next Y42.81%
Revenue Next Year109.31%
SNDX Groups
Sector & Classification
SNDX Financial Highlights
Over the last trailing twelve months SNDX reported a non-GAAP Earnings per Share(EPS) of -3.29. The EPS increased by 11.8% compared to the year before.
Income Statements
Revenue(TTM)172.60M
Net Income(TTM)-285.42M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.88% | ||
| ROE | -441.62% | ||
| Debt/Equity | 5.32 |
Chartmill High Growth Momentum
EPS Q2Q%29.09%
Sales Q2Q%794.9%
EPS 1Y (TTM)11.8%
Revenue 1Y (TTM)628.88%
SNDX Ownership
Ownership
Inst Owners116.08%
Shares88.20M
Float86.32M
Ins Owners1.63%
Short Float %23.98%
Short Ratio14.68
SNDX Latest News, Press Relases and Analysis
19 days ago - By: Chartmill
SNDX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 365.196B | ||
| AMGN | AMGEN INC | 15.32 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 10.94 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.34 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SNDX
Company Profile
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Company Info
IPO: 2016-03-03
SYNDAX PHARMACEUTICALS INC
730 Third Avenue, 9Th Floor
New York City NEW YORK 02451 US
CEO: Briggs W. Morrison
Employees: 298
Phone: 17814191400
SYNDAX PHARMACEUTICALS INC / SNDX FAQ
What does SNDX do?
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
What is the current price of SNDX stock?
The current stock price of SNDX is 24.25 USD. The price decreased by -0.78% in the last trading session.
Does SNDX stock pay dividends?
SNDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SNDX stock?
SNDX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of SNDX stock?
SYNDAX PHARMACEUTICALS INC (SNDX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for SNDX stock?
SYNDAX PHARMACEUTICALS INC (SNDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.29).
Should I buy SNDX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNDX.